Porous Silicon Nanoparticles

  • Hélder A. Santos
  • Ermei Mäkilä
  • Luis M. Bimbo
  • Patrick Almeida
  • Jouni Hirvonen
Chapter

Abstract

Micro- and nano-based technologies are presently recognized as promising potential tools for drug delivery applications in almost every field of health sciences, aiming to overcome the adverse physicochemical properties of conventional drug molecules, which often lead to poor drug bioavailability. A large amount of the new chemical entities developed by the pharmaceutical industry are poorly water-soluble compounds, which in order to subsist as efficient drugs with improved and controllable in vivo behaviour require the aid of more advanced technologies. In this context, porous silicon (PSi) nanocarriers have received considerable attention for the delivery of a wide range of therapeutics, particularly due to their excellent in vivo biocompatibility, easy surface chemical modification and easy control over their porous network structure. The literature has extensively demonstrated the successful use of PSi for controlling the loading and release of poorly water-soluble drugs; however, in this chapter we will mainly focus on the applications of the PSi-based nanoparticles for biomedical applications. In this chapter, we start by addressing the issues of poorly water-soluble drugs and then introduce PSi-based materials as potential drug carriers for such drugs. We then highlight the fabrication methodology of PSi materials, the drug loading and release, and present several examples of the significant potential of PSi in biomedical imaging and in drug delivery applications. These applications exploit these promising features of PSi for future translation to the clinic. We will conclude the chapter with a brief overview of our visions of the future of the PSi nanomaterials and their implications in the pharmaceutical and biomedical field.

Keywords

Permeability Surfactant Crystallization Toxicity SiO2 

Notes

Acknowledgments

Hélder A. Santos acknowledges the Academy of Finland (project numbers 252215 and 256394) and the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013)/ERC Grant agreement number 310892 for financial support. Luis M. Bimbo acknowledges the Finnish Cultural Foundation for financial support.

References

  1. Ainslie KM, Tao SL, Popat KC, Desai TA (2008) In vitro immunogenicity of silicon-based micro- and nanostructured surfaces. ACS Nano 2:1076–1084PubMedCrossRefGoogle Scholar
  2. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420PubMedCrossRefGoogle Scholar
  3. Anderson SHC, Elliott H, Wallis DJ, Canham LT, Powell JJ (2003) Dissolution of different forms of partially porous silicon wafers under simulated physiological conditions. Phys Status Solidi A 197:331–335CrossRefGoogle Scholar
  4. Anglin EJ, Schwartz MP, Ng VP, Perelman LA, Sailor MJ (2004) Engineering the chemistry and nanostructure of porous silicon fabry-pérot films for loading and release of a steroid. Langmuir 20:11264–11269PubMedCrossRefGoogle Scholar
  5. Arroyo-Hernández M, Martín-Palma RJ, Torres-Costa V, Martínez Duart JM (2006) Porous silicon optical filters for biosensing applications. J Non-Cryst Solids 352:2457–2460CrossRefGoogle Scholar
  6. Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27–43PubMedCrossRefGoogle Scholar
  7. Avdeef A (2001) Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1:277–351PubMedCrossRefGoogle Scholar
  8. Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Makila E, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J, Salonen J (2010) Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 4:3023–3032PubMedCrossRefGoogle Scholar
  9. Bimbo LM, Makila E, Laaksonen T, Lehto VP, Salonen J, Hirvonen J, Santos HA (2011a) Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials 32:2625–2633PubMedCrossRefGoogle Scholar
  10. Bimbo LM, Makila E, Raula J, Laaksonen T, Laaksonen P, Strommer K, Kauppinen EI, Salonen J, Linder MB, Hirvonen J, Santos HA (2011b) Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 32:9089–9099PubMedCrossRefGoogle Scholar
  11. Bimbo LM, Peltonen L, Hirvonen J, Santos HA (2012a) Toxicological profile of therapeutic nanodelivery systems. Curr Drug Metab 13:1068–1086PubMedCrossRefGoogle Scholar
  12. Bimbo LM, Sarparanta M, Makila E, Laaksonen T, Laaksonen P, Salonen J, Linder MB, Hirvonen J, Airaksinen AJ, Santos HA (2012b) Cellular interactions of surface modified nanoporous silicon particles. Nanoscale 4:3184–3192PubMedCrossRefGoogle Scholar
  13. Boukherroub R, Wojtyk JTC, Wayner DDM, Lockwood DJ (2002) Thermal hydrosilylation of undecylenic acid with porous silicon. J Electrochem Soc 149:H59–H63CrossRefGoogle Scholar
  14. Canham LT (1995) Bioactive silicon structure fabrication through nanoetching techniques. Adv Mater 7:1033–1037CrossRefGoogle Scholar
  15. Canham LT (1997) Properties of porous silicon. Short Run Press Ltd., LondonGoogle Scholar
  16. Chirvony V, Bolotin V, Matveeva E, Parkhutik V (2006) Fluorescence and 1O2 generation properties of porphyrin molecules immobilized in oxidized nano-porous silicon matrix. J Photochem Photobiol A Chem 181:106–113CrossRefGoogle Scholar
  17. De Stefano L, Rea I, Armenante A, Giardina P, Giocondo M, Rendina I (2007) Self-assembled biofilm of hydrophobins protects the silicon surface in the KOH wet etch process. Langmuir 23:7920–7922PubMedCrossRefGoogle Scholar
  18. De Stefano L, Rea I, De Tommasi E, Rendina I, Rotiroti L, Giocondo M, Longobardi S, Armenante A, Giardina P (2009) Bioactive modification of silicon surface using self-assembled hydrophobins from pleurotus ostreatus. Eur Phys J E Soft Matter 30:181–185PubMedCrossRefGoogle Scholar
  19. Fahr A, Liu X (2007) Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 4:403–416PubMedCrossRefGoogle Scholar
  20. Fang DZ, Striemer CC, Gaborski TR, Mcgrath JL, Fauchet PM (2010) Pore size control of ultrathin silicon membranes by rapid thermal carbonization. Nano Lett 10:3904–3908PubMedCrossRefGoogle Scholar
  21. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3:16–20PubMedCrossRefGoogle Scholar
  22. FDA (1979) Database of select committee on gras substances (scogs) reviews: Silicon dioxides [Online]. Available: http://www.accessdata.fda.gov/scripts/fcn/fcnDetailNavigation.cfm?rpt=scogsListing&id=276. Accessed 30 Nov 2012
  23. Foll H, Christophersen M, Carstensen J, Hasse G (2002) Formation and application of porous silicon. Mat Sci Eng Reports 39:93–141CrossRefGoogle Scholar
  24. Foraker AB, Walczak RJ, Cohen MH, Boiarski TA, Grove CF, Swaan PW (2003) Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res 20:110–116PubMedCrossRefGoogle Scholar
  25. Godin B, Gu J, Serda RE, Ferrati S, Liu X, Chiappini C, Tanaka T, Decuzzi P, Ferrari M (2008) Multistage mesoporous silicon-based nanocarriers: biocompatibility with immune cells and controlled degradation in physiological fluids. Controll Release Newsl 25:9–11PubMedGoogle Scholar
  26. Godin B, Chiappini C, Srinivasan S, Alexander JF, Yokoi K, Ferrari M, Decuzzi P, Liu XW (2012) Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv Funct Mater 22:4225–4235PubMedCrossRefGoogle Scholar
  27. Goh ASW, Chung AYF, Lo RHG, Lau TN, Yu SWK, Chng M, Satchithanantham S, Loong SLE, Ng DCE, Lim BC, Connor S, Chow PKH (2007) A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous(32) (P-32) brachytherapy delivery device—a first-in-man study. Int J Radiat Oncol Biol Phys 67:786–792PubMedCrossRefGoogle Scholar
  28. Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, Desimone JM (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613–11618PubMedCrossRefGoogle Scholar
  29. Grosman A, Ortega C (1997) Chemical composition of “fresh” porous silicon. In: Canham LT (ed) Properties of porous silicon. Short Run Press Ltd., LondonGoogle Scholar
  30. Hamilton B (1995) Porous silicon. Semicond Sci Technol 10:1187CrossRefGoogle Scholar
  31. Hancock BC, Parks M (2000) What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397–404PubMedCrossRefGoogle Scholar
  32. Hart BR, Letant SE, Kane SR, Hadi MZ, Shields SJ, Reynolds JG (2003) New method for attachment of biomolecules to porous silicon. Chem Commun (Camb) 3:322–323CrossRefGoogle Scholar
  33. Heikkila T, Salonen J, Tuura J, Kumar N, Salmi T, Murzin DY, Hamdy MS, Mul G, Laitinen L, Kaukonen AM, Hirvonen J, Lehto VP (2007) Evaluation of mesoporous TCPSI, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 14:337–347PubMedCrossRefGoogle Scholar
  34. Huhtala T, Rytkönen J, Jalanko A, Kaasalainen M, Salonen J, Riikonen R, Närvänen A (2012) Native and complexed IGF-1: biodistribution and pharmacokinetics in infantile neuronal ceroid lipofuscinosis. J Drug Deliv 2012:8CrossRefGoogle Scholar
  35. Jalkanen T, Makila E, Suzuki YI, Urata T, Fukami K, Sakka T, Salonen J, Ogata YH (2012) Studies on chemical modification of porous silicon-based graded-index optical microcavities for improved stability under alkaline conditions. Adv Funct Mater 22:3890–3898CrossRefGoogle Scholar
  36. Jiang W, Kim BY, Rutka JT, Chan WC (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3:145–150PubMedCrossRefGoogle Scholar
  37. Jugdaohsingh R, Anderson SHC, Tucker KL, Elliott H, Kiel DP, Thompson RPH, Powell JJ (2002) Dietary silicon intake and absorption. Am J Clin Nutr 75:887–893PubMedGoogle Scholar
  38. Kaasalainen M, Makila E, Riikonen J, Kovalainen M, Jarvinen K, Herzig KH, Lehto VP, Salonen J (2012) Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations. Int J Pharm 431:230–236PubMedCrossRefGoogle Scholar
  39. Kaukonen AM, Laitinen L, Salonen J, Tuura J, Heikkila T, Limnell T, Hirvonen J, Lehto VP (2007) Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSI) microparticles. Eur J Pharm Biopharm 66:348–356PubMedCrossRefGoogle Scholar
  40. Kilpelainen M, Riikonen J, Vlasova MA, Huotari A, Lehto VP, Salonen J, Herzig KH, Jarvinen K (2009) In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J Control Release 137:166–170PubMedCrossRefGoogle Scholar
  41. Kilpelainen M, Monkare J, Riikonen J, Vlasova M, Salonen J, Lehto VP, Herzig KH, Jarvinen K (2010) Mesoporous silicon microparticles as carriers for peptides. J Control Release 148:e43–e44PubMedCrossRefGoogle Scholar
  42. Kilpelainen M, Monkare J, Vlasova MA, Riikonen J, Lehto VP, Salonen J, Jarvinen K, Herzig KH (2011) Nanostructured porous silicon microparticles enable sustained peptide (melanotan II) delivery. Eur J Pharm Biopharm 77:20–25PubMedCrossRefGoogle Scholar
  43. Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA (2011) Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm 414:148–156PubMedCrossRefGoogle Scholar
  44. Korotcenkov G, Cho BK (2010) Silicon porosification: state of the art. Crit Rev Solid State Mater Sci 35:153–260CrossRefGoogle Scholar
  45. Kovalainen M, Monkare J, Makila E, Salonen J, Lehto VP, Herzig KH, Jarvinen K (2012) Mesoporous silicon (PSi) for sustained peptide delivery: effect of PSi microparticle surface chemistry on peptide YY3-36 release. Pharm Res 29:837–846PubMedCrossRefGoogle Scholar
  46. Laaksonen T, Santos H, Vihola H, Salonen J, Riikonen J, Heikkila T, Peltonen L, Kumar N, Murzin DY, Lehto VP, Hirvonen J (2007) Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem Res Toxicol 20:1913–1918PubMedCrossRefGoogle Scholar
  47. Lees IN, Lin HH, Canaria CA, Gurtner C, Sailor MJ, Miskelly GM (2003) Chemical stability of porous silicon surfaces electrochemically modified with functional alkyl species. Langmuir 19:9812–9817CrossRefGoogle Scholar
  48. Lehto VP, Salonen J, Santos HA, Riikonen J (2012) Nanostructured silicon based materials as a drug delivery system for insoluble drugs. In: Douroumis D, Fahr A (eds) Drug delivery strategies for poorly water-soluble drugs. Wiley-Blackwell, WeinheimGoogle Scholar
  49. Limnell T, Riikonen J, Salonen J, Kaukonen AM, Laitinen L, Hirvonen J, Lehto VP (2007) Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. Int J Pharm 343:141–147PubMedCrossRefGoogle Scholar
  50. Linder MB (2009) Hydrophobins: proteins that self assemble at interfaces. Curr Opin Colloid Interface Sci 14:356–363CrossRefGoogle Scholar
  51. Liu D, Mäkilä E, Zhang H, Herranz B, Kaasalainen M, Kinnari P, Salonen J, Hirvonen J, Santos HA (2013) Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release. Adv Funct Mater 23(15):1893–1902CrossRefGoogle Scholar
  52. Low SP, Williams KA, Canham LT, Voelcker NH (2010) Generation of reactive oxygen species from porous silicon microparticles in cell culture medium. J Biomed Mater Res A 93:1124–1131PubMedGoogle Scholar
  53. Mäkilä E, Bimbo LM, Kaasalainen M, Herranz B, Airaksinen AJ, Heinonen M, Kukk E, Hirvonen J, Santos HA, Salonen J (2012) Amine modification of thermally carbonized porous silicon with silane coupling chemistry. Langmuir 28:14045–14054PubMedCrossRefGoogle Scholar
  54. Mattei G, Valentini V, Yakovlev VA (2002) An FTIR study of porous silicon layers exposed to humid air with and without pyridine vapors at room temperature. Surf Sci 502–503:58–62CrossRefGoogle Scholar
  55. Mitragotri S, Lahann J (2009) Physical approaches to biomaterial design. Nat Mater 8:15–23PubMedCrossRefGoogle Scholar
  56. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318PubMedGoogle Scholar
  57. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311–330PubMedCrossRefGoogle Scholar
  58. Nel A, Xia T, Madler L, Li N (2006) Toxic potential of materials at the nanolevel. Science 311:622–627PubMedCrossRefGoogle Scholar
  59. Oberdorster G (2010) Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 267:89–105PubMedCrossRefGoogle Scholar
  60. Pap AE, Kordas K, George TF, Leppavuori S (2004) Thermal oxidation of porous silicon: study on reaction kinetics. J Phys Chem B 108:12744–12747CrossRefGoogle Scholar
  61. Park JH, Gu L, Von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ (2009) Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 8:331–336PubMedCrossRefGoogle Scholar
  62. Pastor E, Matveeva E, Valle-Gallego A, Goycoolea FM, Garcia-Fuentes M (2011) Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles. Colloids Surf B Biointerfaces 88:601–609PubMedCrossRefGoogle Scholar
  63. Popplewell JF, King SJ, Day JP, Ackrill P, Fifield LK, Cresswell RG, Di Tada ML, Liu K (1998) Kinetics of uptake and elimination of silicic acid by a human subject: a novel application of Si-32 and accelerator mass spectrometry. J Inorg Biochem 69:177–180PubMedCrossRefGoogle Scholar
  64. Reffitt DM, Jugdaohsingh R, Thompson RP, Powell JJ (1999) Silicic acid: its gastrointestinal uptake and urinary excretion in man and effects on aluminium excretion. J Inorg Biochem 76:141–147PubMedCrossRefGoogle Scholar
  65. Salonen J, Lehto V-P (2008) Fabrication and chemical surface modification of mesoporous silicon for biomedical applications. Chem Eng J 137:162–172CrossRefGoogle Scholar
  66. Salonen J, Lehto VP, Björkqvist M, Laine E, Niinistö L (2000) Studies of thermally-carbonized porous silicon surfaces. Phys Status Solidi A 182:123–126CrossRefGoogle Scholar
  67. Salonen J, Björkqvist M, Laine E, Niinistö L (2004) Stabilization of porous silicon surface by thermal decomposition of acetylene. Appl Surf Sci 225:389–394CrossRefGoogle Scholar
  68. Salonen J, Laitinen L, Kaukonen AM, Tuura J, Bjorkqvist M, Heikkila T, Vaha-Heikkila K, Hirvonen J, Lehto VP (2005) Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 108:362–374PubMedCrossRefGoogle Scholar
  69. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP (2008) Mesoporous silicon in drug delivery applications. J Pharm Sci 97:632–653PubMedCrossRefGoogle Scholar
  70. Sam S, Touahir L, Andresa Salvador J, Allongue P, Chazalviel JN, Gouget-Laemmel AC, Henry De Villeneuve C, Moraillon A, Ozanam F, Gabouze N, Djebbar S (2009) Semiquantitative study of the EDC/NHS activation of acid terminal groups at modified porous silicon surfaces. Langmuir 26:809–814CrossRefGoogle Scholar
  71. Sam S, Chazalviel JN, Gouget-Laemmel AC, Ozanam F, Allongue P, Henry De Villeneuve C, Gabouze N, Djebbar S (2010) Covalent immobilization of amino acids on the porous silicon surface. Surf Interface Anal 42:515–518CrossRefGoogle Scholar
  72. Santos HA, Hirvonen J (2012) Nanostructured porous silicon materials: potential candidates for improving drug delivery. Nanomedicine (Lond) 7:1281–1284CrossRefGoogle Scholar
  73. Santos HA, Riikonen J, Salonen J, Makila E, Heikkila T, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J (2010) In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 6:2721–2731PubMedCrossRefGoogle Scholar
  74. Santos HA, Bimbo LM, Lehto VP, Airaksinen AJ, Salonen J, Hirvonen J (2011a) Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol 8:228–249PubMedCrossRefGoogle Scholar
  75. Santos HA, Salonen J, Bimbo LM, Lehto VP, Peltonen L, Hirvonen J (2011b) Mesoporous materials as controlled drug delivery formulations. J Drug Deliv Sci Technol 21:139–155Google Scholar
  76. Santos HA, Bimbo LM, Herranz B, Shahbazia M-A, Hirvonen J, Salonen J (2013a) Nanostructured porous silicon in preclinical imaging: moving from bench to bedside. J Mater Res 28:152–164CrossRefGoogle Scholar
  77. Santos HA, Salonen J, Bimbo LM (2013b) Porous silicon for drug delivery. In: Uversky VN, Kretsinger RH, Permyakov EA (eds) Encyclopedia of metalloproteins. Springer, New YorkGoogle Scholar
  78. Sarparanta M, Makila E, Heikkila T, Salonen J, Kukk E, Lehto VP, Santos HA, Hirvonen J, Airaksinen AJ (2011) 18F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. Mol Pharm 8:1799–1806PubMedCrossRefGoogle Scholar
  79. Sarparanta M, Bimbo LM, Rytkonen J, Makila E, Laaksonen TJ, Laaksonen P, Nyman M, Salonen J, Linder MB, Hirvonen J, Santos HA, Airaksinen AJ (2012a) Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Mol Pharm 9:654–663PubMedCrossRefGoogle Scholar
  80. Sarparanta MP, Bimbo LM, Makila EM, Salonen JJ, Laaksonen PH, Helariutta AMK, Linder MB, Hirvonen JT, Laaksonen TJ, Santos HA, Airaksinen AJ (2012b) The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials 33:3353–3362PubMedCrossRefGoogle Scholar
  81. Schwartz MP, Yu C, Alvarez SD, Migliori B, Godin D, Chao L, Sailor MJ (2007) Using an oxidized porous silicon interferometer for determination of relative protein binding affinity through non-covalent capture probe immobilization. Phys Status Solidi A 204:1444–1448CrossRefGoogle Scholar
  82. Sciacca B, Alvarez SD, Geobaldo F, Sailor MJ (2010) Bioconjugate functionalization of thermally carbonized porous silicon using a radical coupling reaction. Dalton Trans 39:10847–10853PubMedCrossRefGoogle Scholar
  83. Sciacca B, Secret E, Pace S, Gonzalez P, Geobaldo F, Quignard F, Cunin F (2011) Chitosan-functionalized porous silicon optical transducer for the detection of carboxylic acid-containing drugs in water. J Mater Chem 21:2294–2302CrossRefGoogle Scholar
  84. Serda RE, Mack A, Pulikkathara M, Zaske AM, Chiappini C, Fakhoury JR, Webb D, Godin B, Conyers JL, Liu XW, Bankson JA, Ferrari M (2010) Cellular association and assembly of a multistage delivery system. Small 6:1329–1340PubMedCrossRefGoogle Scholar
  85. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M (2011) Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta 1810:317–329PubMedCrossRefGoogle Scholar
  86. Shahbazi MA, Santos HA (2013) Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 14:28–56PubMedCrossRefGoogle Scholar
  87. Shahbazi M-A, Herranz B, Santos HA (2012) Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter 2Google Scholar
  88. Singh A, Worku ZA, Van Den Mooter G (2011) Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv 8(10):1361–1378PubMedCrossRefGoogle Scholar
  89. Sripanyakorn S, Jugdaohsingh R, Elliott H, Walker C, Mehta P, Shoukru S, Thompson RPH, Powell JJ (2004) The silicon content of beer and its bioavailability in healthy volunteers. Br J Nutr 91:403–409PubMedCrossRefGoogle Scholar
  90. Sweetman MJ, Shearer CJ, Shapter JG, Voelcker NH (2011) Dual silane surface functionalization for the selective attachment of human neuronal cells to porous silicon. Langmuir 27:9497–9503PubMedCrossRefGoogle Scholar
  91. Tahvanainen M, Rotko T, Mäkilä E, Santos HA, Neves D, Laaksonen T, Kallonen A, Hämäläinen K, Peura M, Serimaa R, Salonen J, Hirvonen J, Peltonen L (2012) Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles. Int J Pharm 422:125–131PubMedCrossRefGoogle Scholar
  92. Tasciotti E, Liu XW, Bhavane R, Plant K, Leonard AD, Price BK, Cheng MMC, Decuzzi P, Tour JM, Robertson F, Ferrari M (2008) Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 3:151–157PubMedCrossRefGoogle Scholar
  93. Tay L, Rowell NL, Poitras D, Fraser JW, Lockwood DJ, Boukherroub R (2004) Bovine serum albumin adsorption on passivated porous silicon layers. Can J Chem 82:1545–1553CrossRefGoogle Scholar
  94. Thommes M (2010) Physical adsorption characterization of nanoporous materials. Chem Ing Tech 82:1059–1073CrossRefGoogle Scholar
  95. Vaccari L, Canton D, Zaffaroni N, Villa R, Tormen M, Di Fabrizio E (2006) Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent. Microelectron Eng 83:1598–1601CrossRefGoogle Scholar
  96. Vale N, Mäkilä E, Salonen J, Gomes P, Hirvonen J, Santos HA (2012) New times, new trends for ethionamide: in vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles. Eur J Pharm Biopharm 81:314–323PubMedCrossRefGoogle Scholar
  97. Wang F, Hui H, Barnes TJ, Barnett C, Prestidge CA (2010) Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol Pharm 7:227–236PubMedCrossRefGoogle Scholar
  98. Wu J, Sailor M (2009) Chitosan hydrogel-capped porous SiO2 as a pH responsive nano-valve for triggered release of insulin. Adv Funct Mater 19:733–741CrossRefGoogle Scholar
  99. Wu EC, Park J-H, Park J, Segal E, Cunin FDR, Sailor MJ (2008) Oxidation-triggered release of fluorescent molecules or drugs from mesoporous si microparticles. ACS Nano 2:2401–2409PubMedCrossRefGoogle Scholar
  100. Zhang K, Loong SL, Connor S, Yu SW, Tan SY, Ng RT, Lee KM, Canham L, Chow PK (2005) Complete tumor response following intratumoral 32P biosilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin Cancer Res 11:7532–7537PubMedCrossRefGoogle Scholar
  101. Zhang F, Sautter K, Larsen AM, Findley DA, Davis RC, Samha H, Linford MR (2010) Chemical vapor deposition of three aminosilanes on silicon dioxide: surface characterization, stability, effects of silane concentration, and cyanine dye adsorption. Langmuir 26:14648–14654PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hélder A. Santos
    • 1
  • Ermei Mäkilä
    • 1
    • 2
  • Luis M. Bimbo
    • 1
  • Patrick Almeida
    • 1
  • Jouni Hirvonen
    • 1
  1. 1.Division of Pharmaceutical Technology, Faculty of PharmacyUniversity of HelsinkiHelsinkiFinland
  2. 2.Laboratory of Industrial Physics, Department of Physics and AstronomyUniversity of TurkuTurkuFinland

Personalised recommendations